The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Using MRD after autoSCT as a benchmark for consolidation strategies in myeloma
Susan Bal, MD, University of Alabama at Birmingham, Birmingham, AL, discusses the significance of measurable residual disease (MRD) following consolidation treatment with autologous stem cell transplantation (autoSCT) in multiple myeloma. Her research highlights that MRD negativity rates improve significantly after autoSCT, particularly benefiting high-risk patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
